Navigation Links
Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Date:11/13/2012

MOUNTAIN VIEW, Calif., Nov. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome." Four clinical trial sites have been selected in the United States: Lucile Packard Children's Hospital, Stanford University Medical Center – Palo Alto, California; Akron Children's Hospital – Akron, Ohio; Seattle Children's Hospital – Seattle, Washington; and Texas Children's Hospital, Baylor University – Houston, Texas.

The trial is a placebo-controlled study lasting six months, and then extending an additional six months, during which all subjects will receive EPI-743. Subjects must be between one and twelve years old, possess genetic confirmation of Leigh syndrome, and meet certain disease severity criteria. More information on the study specifics is available on ClinicalTrials.gov.

The primary endpoint of the clinical trial is the Newcastle Paediatric Mitochondrial Disease Scale. Secondary endpoints include neurologic, muscular, imaging, and biomarker indices. The study design was based on positive phase 2A data recently reported in the journal Molecular Genetics and Metabolism, "EPI-743 reverses the progression of the pediatric mitochondrial disease- genetically defined Leigh Syndrome" 107 (2012) 383-388.

Leigh Syndrome

Leigh syndrome is an inherited lethal, progressive, predominately pediatric, neuromuscular disorder for which there are no approved treatments. Initially described in 1951, the hallmarks of the disease include death of central nervous system regions responsible for the control of breathing and coordination of movement. Leigh syndrome is a member of a larger family of diseases called mitochondrial disease, which share as a common biochemical mechanism defects in cellular energy metabolism.

EPI-743

EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of Leigh syndrome and other inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress.

Edison Pharmaceuticals

Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases.

Clinical Study Site Information

Akron Children's Hospital
htonni@chmca.org

Lucile Packard Children's Hospital, Stanford University Medical Center
kconnors@stanford,edu

Seattle Children's Hospital
laurie.guidry@seattlechildrens.org

Texas Children's Hospital, Baylor University
catherine.loffredo@bcm.edu


'/>"/>
SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
2. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
5. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
6. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
7. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
8. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017   Seno Medical Instruments, Inc. , the ... through the development of an opto-acoustic (OA/US) imaging device, ... as SVP of Engineering. Mr. Miller previously served as ... with headquarters in Bothell, Washington . ... career to the development of innovative medical imaging products ...
(Date:1/18/2017)... -- Tarix Orphan LLC today announced that the U.S. Food ... (RPD) designation for the company,s drug candidate TXA127 for ... rare genetic skin disorder. There are currently no approved ... care. "The RPD designation for TXA127 in ... the FDA in this indication," said Richard Franklin ...
(Date:1/18/2017)... 18, 2017 After the recent election ... use of cannabis both for medical and recreational purposes are ... open to the use of cannabis, but the focus is ... Arcview Market Research, the North American legal cannabis market posted ... previous year. The research projects sales will grow at a ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed firm ... central Maryland and the DC region, is inaugurating a charity event aimed at fighting ... year, making it the #1 killer in America. However, heart disease is largely preventable, ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, ... Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, ... endure and pass through tough times, Dr. Bernie Siegel energizes listeners to live ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
Breaking Medicine News(10 mins):